急性脑出血积极与保守降压策略:随机对照试验的系统评价与荟萃分析
该系统评价与荟萃分析纳入8项随机开放标签盲法终点试验,共12,669例急性脑出血患者(中位年龄63岁,60%男性),比较积极与保守降压策略。主要结果显示两组在优良功能预后(RR 1.07,95%CI 0.99-1.16)、良好功能预后(RR 1.09,95%CI 0.99-1.20)、90天死亡率(RR 0.90,95%CI 0.77-1.05)和血肿扩大(RR 0.85,95%CI 0.66-1.10)上均无显著差异。积极降压组不良事件更少(RR 0.87,95%CI 0.76-0.99,P=0.03)。敏感性分析显示积极降压对良好恢复有显著获益(RR 1.05,95%CI 1.01-1.10,P=0.02),但亚组分析未证实。
要点
- 8项RCT共12,669例急性脑出血患者,积极与保守降压在优良功能预后上无显著差异(RR 1.07,95%CI 0.99-1.16)。
- 90天死亡率两组无显著差异(RR 0.90,95%CI 0.77-1.05,P=0.18)。
- 血肿扩大两组无显著差异(RR 0.85,95%CI 0.66-1.10,P=0.22)。
- 积极降压与更少不良事件相关(RR 0.87,95%CI 0.76-0.99,P=0.03),亚组分析一致支持(RR 0.81,95%CI 0.74-0.88)。
- 敏感性分析示积极降压对良好恢复有显著获益(RR 1.05,95%CI 1.01-1.10),但亚组分析未证实(RR 1.09,95%CI 0.97-1.23)。
适用人群与场景
- 急性脑出血成人患者(中位年龄63岁,60%男性),来自8项随机开放标签盲法终点试验。
- 原文未提及具体纳入/排除标准、急诊/ICU/院前场景及病情阶段。
诊断标准与关键阈值
- 原文未提及具体诊断标准、血压阈值或评分界值。
处置流程与药物剂量
- 原文未提及具体药物名称、剂量、给药途径、频次、疗程或目标血压值。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:系统评价与荟萃分析,纳入8项随机开放标签盲法终点试验,共12,669例急性脑出血患者(中位年龄63岁,60%男性)。
- 干预与对照:积极降压 vs 保守降压。
- 主要终点:优良功能预后无显著差异(RR 1.07,95%CI 0.99-1.16,P=0.94,I2=33%);良好功能预后无显著差异(RR 1.09,95%CI 0.99-1.20,P=0.07,I2=51%)。
- 90天死亡率无显著差异(RR 0.90,95%CI 0.77-1.05,P=0.18,I2=0%);血肿扩大无显著差异(RR 0.85,95%CI 0.66-1.10,P=0.22,I2=48%)。
- 不良事件:积极降压组更少(RR 0.87,95%CI 0.76-0.99,P=0.03,I2=59%);亚组分析一致支持(RR 0.81,95%CI 0.74-0.88,P<0.01,I2=0%)。
- 敏感性分析:积极降压对良好恢复有显著获益(RR 1.05,95%CI 1.01-1.10,P=0.02,I2=0%),但亚组分析未证实(RR 1.09,95%CI 0.97-1.23,P=0.14,I2=61%)。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与荟萃分析。
- 局限:纳入试验为开放标签设计;部分终点存在异质性(良好功能预后I2=51%,血肿扩大I2=48%,不良事件I2=59%);敏感性分析获益未在亚组分析中证实。
对床旁实践的改变
- 原文结果提示积极与保守降压在功能预后、死亡和血肿扩大上效果相似,积极降压可能减少不良事件,但具体血压目标及药物方案原文未提及,不能据此改变具体降压目标或药物选择。
- 适用人群为急性脑出血成人患者,不适用人群原文未提及。
- 常见陷阱:敏感性分析中积极降压对良好恢复的获益未在亚组分析中证实,不应据此夸大积极降压的功能获益。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Intracerebral hemorrhage carries high mortality and long-term disability. The optimal blood pressure (BP) management strategy-aggressive vs. conservative lowering-remains uncertain. This review compares both strategies.
DATA SOURCES: Articles from PubMed, Web of Science, Embase, and Cochrane were screened to August 2025.
STUDY SELECTION: Only randomized open-label blinded-endpoint trials were included.
DATA EXTRACTION: Patient characteristics, inclusion criteria, interventions, and outcomes were independently extracted by two authors; conflicts were resolved by a third.
DATA SYNTHESIS: Eight randomized controlled trials (12,669 patients; median age 63 yr; 60% male) met inclusion. No significant differences emerged between aggressive and conservative strategies for excellent functional outcome (risk ratio [RR], 1.07; 95% CI, 0.99-1.16; p = 0.94; I2 = 33%), good functional outcome (RR, 1.09; 95% CI, 0.99-1.20; p = 0.07; I2 = 51%), 90-day mortality (RR, 0.90; 95% CI, 0.77-1.05; p = 0.18; I2 = 0%), or hematoma growth (RR, 0.85; 95% CI, 0.66-1.10; p = 0.22; I2 = 48%). Aggressive BP lowering was associated with fewer adverse events (RR, 0.87; 95% CI, 0.76-0.99; p = 0.03; I2 = 59%). Sensitivity analyses showed significant benefits of the aggressive approach for good recovery (RR, 1.05; 95% CI, 1.01-1.10; p = 0.02; I2 = 0%), although not confirmed in the subgroup analyses (RR, 1.09; 95% CI, 0.97-1.23; p = 0.14; I2 = 61%). For adverse events, subgroup analyses consistently favored the aggressive strategy (RR, 0.81; 95% CI, 0.74-0.88; p < 0.01; I2 = 0%). No clear association with hematoma growth emerged, largely due to heterogeneity.
CONCLUSIONS: Aggressive and conservative BP lowering yielded similar outcomes for functional recovery, mortality, and hematoma growth. Aggressive BP lowering was linked to fewer adverse events, with some subgroup analyses suggesting modest functional benefits.
参考来源
- Semione G, Ferreira MY, Gunkan A, et al. Aggressive vs. Conservative Blood Pressure Reduction in Acute Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Crit Care Med. 2026. PMID: 42484370. doi:10.1097/CCM.0000000000007240
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。